In 2017, Novartis seized the spotlight by winning FDA approval of the first CAR-T immunotherapy, CTL019 (Kymriah) for acute lymphoblastic leukemia (ALL). While noteworthy in and of itself, this occurred the same week that Gilead Sciences reported its $11 billion acquisition of Kite Pharma, a leader in CAR-T immunotherapy for cancer.
This opens up the conversation about the classification of new therapies employing genetic modifications. Are they all gene therapy? A quick study of the social media posts on the approval of Kymriah reveals that there are a variety of opinions on what constitutes gene therapy. And you may be surprised by some of those opinions. Read this white paper highlighting the confusion that abounds around the classification of the new CAR-T therapies.
Download this whitepaper to learn more about gene therapy.